Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization.

Ultragenyx stock jumped more than 12% following the announcement of the Fayuvi approval. But the stock is still down nearly 40% this year. The more important question for investor ...

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem.

Stellantis N.V. (NYSE:STLA) is stepping up investments in its European manufacturing operations even as it targets €6 billion ...